State of Alaska Department of Revenue’s Coherus Oncology CHRS Stock Holding History

State of Alaska Department of Revenue’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-43,992	Closed	-$187K	–	1615
2023 Q2	$187K	Sell	43,992 -211	-0.5%	-$1.25K	﹤0.01%	1597
2023 Q1	$302K	Sell	44,203 -749	-2%	-$5.81K	﹤0.01%	1537
2022 Q4	$356K	Buy	44,952 +193	+0.4%	+$1.49K	﹤0.01%	1493
2022 Q3	$430K	Sell	44,759 -3,787	-8%	-$38.3K	0.01%	1374
2022 Q2	$351K	Buy	48,546 +4,210	+9%	+$36.6K	﹤0.01%	1492
2022 Q1	$572K	Sell	44,336 -790	-2%	-$10K	0.01%	1333
2021 Q4	$720K	Sell	45,126 -1,180	-3%	-$20.6K	0.01%	1263
2021 Q3	$744K	Buy	46,306 +209	+0.5%	+$3.06K	0.01%	1265
2021 Q2	$637K	Buy	46,097 +2,738	+6%	+$38.8K	0.01%	1325
2021 Q1	$633K	Sell	43,359 -5,990	-12%	-$102K	0.01%	1309
2020 Q4	$857K	Sell	49,349 -9,491	-16%	-$169K	0.01%	1050
2020 Q3	$1.08M	Buy	58,840 +1,310	+2%	+$24.4K	0.01%	834
2020 Q2	$1.03M	Buy	+57,530	New	+$974K	0.01%	866

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

State of Alaska Department of Revenue's CHRS Position: Q3 2023 in Review

State of Alaska Department of Revenue sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 43,992 shares — an estimated $187K sold.

State of Alaska Department of Revenue first reported a position in CHRS in Q2 2020 and held it in 13 quarters. The position peaked at $1.08M in Q3 2020. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

State of Alaska Department of Revenue reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
State of Alaska Department of Revenue sold 43,992 Coherus Oncology shares in Q3 2023, an estimated $187K.
State of Alaska Department of Revenue first reported a position in Coherus Oncology in Q2 2020 and held it in 13 quarters.
State of Alaska Department of Revenue's Coherus Oncology position peaked at $1.08M in Q3 2020.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on State of Alaska Department of Revenue's 13F filing for Q3 2023, filed 16 Oct 2023.